Craig Hendrix is the Wellcome Professor and Director, Division of Clinical Pharmacology, at Johns Hopkins University School of Medicine. He trained in infectious diseases and clinical pharmacology at Hopkins before 10 years as an Air Force physician and 22 years at Johns Hopkins. Dr. Hendrix’s primary research focus is clinical pharmacology of HIV pre-exposure prophylaxis. Among other research projects, he’s involved as Principal Investigator or Project Leader in a variety of early phase topical PrEP program project grants funded by NIH. He also serves as director of the Pharmacology Group for both the Microbicide Trials Network and HIV Prevention Trials Network. In 2018, he was recognized by ACCP with the Distinguished Investigator Award.
At the completion of this educational session, learners will:
- Describe the value of CHOICE among HIV prevention platforms.
- Identify special population concerns with oral PrEP, including transgender women and pregnant women.
- Discuss ongoing development of topical microbicides, including vaginal and rectal microbicides.
- Discuss ongoing development of long-acting PrEP, including antiretrovirals and monoclonal antibodies.
This CME activity has approved for AMA PRA Category 1 Credit™
on April 16, 2019 and will terminate April 15, 2022.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
Dr. Craig W. Hendrix (Presenter) had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Ongoing clinical research contracts with Gilead and ViiV. Dr. Hendrix submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; and Merck & Co.
To obtain CME credit for this PRN program, please visit the PRN Courses Page
at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.